title: Is growth hormone bad for your heart? Cardiovascular impact of GH deficiency and of acromegaly.
abstract: At present, there is growing evidence implicating GH and/or IGF-I in the intricate cascade of events connected with the regulation of heart development and hypertrophy. Moreover, GH excess and/or deficiency have been shown to include in their advanced clinical manifestations almost always an impaired cardiac function, which may reduce life expectancy. This finding is related both to a primitive impairment of heart structure and function and to metabolic changes such as hyperlipidemia, increase of body fat and premature atherosclerosis. Patients with childhood or adulthood-onset GH deficiency have a reduced left ventricular mass and ejection fraction and the indexes of left ventricular systolic function remain markedly depressed during exercise. Conversely, in acromegaly the cardiac enlargement, which is disproportionate to the increase in size of other internal body organs, has been a rather uniform finding. The severity of the acromegalic cardiomyopathy was reported to be correlated better with the disease duration than with circulating GH and/or IGF-I levels. Myocardial hypertrophy with interstitial fibrosis, lymphomononuclear infiltration and areas of monocyte necrosis often results in concentric hypertrophy of both ventricles. The treatment of GH deficiency and excess improved cardiac function. Interestingly, based on the evidence that GH increases cardiac mass, recombinant GH was administered to patients with idiopathic dilated cardiomyopathy. It increased the myocardial mass and reduced the size of the left ventricular chamber, resulting in improvement of hemodynamics, myocardial energy metabolism and clinical status. These promising results open new perspectives for the use of GH in heart failure.
authors.affiliation: Department of Molecular and Clinical Endocrinology, Federico II University, Naples, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Lombardi
authors.forename: A
authors.initials: A
authors.lastname: Colao
authors.forename: P
authors.initials: P
authors.lastname: Marzullo
authors.forename: D
authors.initials: D
authors.lastname: Ferone
authors.forename: S
authors.initials: S
authors.lastname: Longobardi
authors.forename: V
authors.initials: V
authors.lastname: Esposito
authors.forename: B
authors.initials: B
authors.lastname: Merola
mesh_terms: D000172:Acromegaly / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism; D000328:Adult; D000368:Aged; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000209:etiology* / Q000378:metabolism; D013006:Growth Hormone / Q000172:deficiency* / Q000378:metabolism; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use
chemical_list: D006728:Hormones; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone; D015282:Octreotide